Sign In
Buy CUE
$26.84
-3.56 (-11.71%)
At Close: Jul 31, 2026
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
08:00am, Thursday, 26'th Mar 2026
Virtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
04:05pm, Monday, 16'th Mar 2026
BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mo
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
08:00am, Monday, 09'th Mar 2026
BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mo
In two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Proof-of-concept studies reinforce promising preclinical profile and therapeutic potential of CUE-401 BOSTON, Mass.,
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
08:00am, Thursday, 12'th Feb 2026
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod
Cue Biopharma (NASDAQ:CUE) Shares Up 34.8% – What’s Next?
04:47am, Sunday, 28'th Dec 2025
Cue Biopharma, Inc. (NASDAQ: CUE - Get Free Report)'s stock price shot up 34.8% during mid-day trading on Friday. The company traded as high as $0.3324 and last traded at $0.3248. 7,086,842 shares cha
Cue Biopharma Announces Pricing of $10 Million Public Offering
08:00am, Friday, 19'th Dec 2025
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu
Cue Biopharma Announces Proposed Public Offering
04:02pm, Thursday, 18'th Dec 2025
BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates
06:26pm, Wednesday, 12'th Nov 2025
Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago.
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
04:05pm, Wednesday, 12'th Nov 2025
Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
08:00am, Thursday, 06'th Nov 2025
Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100 series of Immuno-STATs® Novel therapeutic
Usman Azam, M.D., is appointed President and Chief Executive Officer of Cue Biopharma, effective September 29, 2025 Daniel Passeri, Chief Executive Officer of Cue Biopharma, transitions to Strategic A
Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
08:00am, Thursday, 21'st Aug 2025
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
08:00am, Wednesday, 13'th Aug 2025
BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
06:11pm, Tuesday, 12'th Aug 2025
Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.2 per share a year ago.
